Small molecules anti-HIV therapeutics targeting CXCR4.

Small molecules anti-HIV therapeutics targeting CXCR4. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Small molecules anti-HIV therapeutics targeting CXCR4. Abstract Text:

Fedora Grande,Antonio Garofalo,Nouri Neamati,

HIV cellular entry is a multistep process that requires the interaction of a viral envelope glycoprotein (gp120) and a host receptor (CD4) followed by binding to a co-receptor. The CC-chemokine receptor 5 (CCR5) and CXC-chemokine receptor 4 (CXCR4) have been identified as the major HIV co-receptors and therefore are promising targets for the development of new anti-HIV drugs. CXCR4 is also involved in several diseases such as angiogenesis, metabolic and neurological disorders, rheumatoid arthritis and in different forms of metastatic cancer. Herein, we present a review focusing on small molecule CXCR4 antagonists. These compounds are divided into 11 classes that include cyclic penta- and tetrapeptides, diketopiperazine mimetics, bicyclams, non-bicyclams, tetrahydroquinolines, thiazolylisothiourea derivatives, benzodiazepines, alkyl amine analogs and non-peptides derivatives, dipicolylamine-zinc(II) complexes, ampelopsin and distamycin analogs. The most advanced CXCR4 antagonists documented are bicyclam derivatives, which are specific CXCR4 antagonists and exhibit potency in the nanomolar range. Further development of selective CXCR4 antagonists continues to be crucial for the design of second generation of anti-HIV drugs. We aim to provide a comprehensive summary of diverse structural templates that could be useful for optimization and discovery of novel CXCR4 antagonists.

Small molecules anti-HIV therapeutics targeting CXCR4. Publishing Authors By Initials

F Grande,A Garofalo,N Neamati,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Small molecules anti-HIV therapeutics targeting CXCR4. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current pharmaceutical design

VOLUME: 14

Page Numbers: 385-404

Journal Abbreviation: Curr. Pharm. Des.

ISSN: 1873-4286

DAY: 21

MONTH: 02

YEAR: 2008

Small molecules anti-HIV therapeutics targeting CXCR4. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9602487

Small molecules anti-HIV therapeutics targeting CXCR4. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Small molecules anti-HIV therapeutics targeting CXCR4. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Small molecules anti-HIV therapeutics targeting CXCR4.

AFFILIATION: Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90089, USA.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Pharm Des

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Small molecules anti-HIV therapeutics targeting CXCR4 Related Publications

• Anti-infectives clinical progress of HIV-1 integrase inhibitors.
• Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy.
• Design and Synthesis of Bis-amide and Hydrazide-containing Derivatives of Malonic Acid as Potential HIV-1 Integrase Inhibitors.
• Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors.
• Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1 integrase inhibitors.
• Evaluation of asthmatic patients referred to jahrom hospital and clinic.
• Four-tiered pi interaction at the dimeric interface of HIV-1 integrase critical for DNA integration and viral infectivity.
• Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: Insight into integrase-DNA complex formation and catalysis.
• Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation.
• Small molecules anti-HIV therapeutics targeting CXCR4.
• Substituted 2-pyrrolinone inhibitors of HIV-1 integrase.
• Synthesis, anti-HIV-1 integrase, and cytotoxic activities of 4-chloro-N-(4-oxopyrimidin-2-yl)-2-mercaptobenzenesulfonamide derivatives.